Myrobalan wins grant for MS remyelination candidate MRO-002 - Multiple Sclerosis News Today
Myrobalan's experimental therapy MRO-002 is a GPR17 antagonist that's made to promote myelin repair in people with MS and other conditions.
Search Group
Share To
Comments
About Screade
Screade® Inc. version f7eb701, copyright 2016 - 2025
Blocked Users
Customize Dark Theme
Forgot your password?
Forgot your password?
Invite your friends
Please type emails of people you want to invite, we will send them invitation email on your behalf. Separate emails with comma if you want to invite multiple friends.
Comments